Gregory T. Lucier Buys 2,000 Shares of NuVasive, Inc. (NUVA) Stock
NuVasive, Inc. (NASDAQ:NUVA) CEO Gregory T. Lucier acquired 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The stock was purchased at an average cost of $61.52 per share, with a total value of $123,040.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NuVasive, Inc. (NUVA) traded down 0.20% during midday trading on Tuesday, hitting $61.39. The stock had a trading volume of 672,015 shares. The firm has a 50 day moving average price of $70.61 and a 200 day moving average price of $73.61. The stock has a market cap of $3.12 billion, a PE ratio of 96.68 and a beta of 1.06. NuVasive, Inc. has a one year low of $56.70 and a one year high of $81.68.
NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. The company had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.40 earnings per share. Equities analysts expect that NuVasive, Inc. will post $2.00 EPS for the current year.
WARNING: “Gregory T. Lucier Buys 2,000 Shares of NuVasive, Inc. (NUVA) Stock” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/gregory-t-lucier-buys-2000-shares-of-nuvasive-inc-nuva-stock/1530331.html.
Institutional investors have recently made changes to their positions in the company. Great West Life Assurance Co. Can boosted its position in shares of NuVasive by 3.8% in the first quarter. Great West Life Assurance Co. Can now owns 30,699 shares of the medical device company’s stock worth $2,291,000 after buying an additional 1,122 shares in the last quarter. Geneva Advisors LLC raised its stake in shares of NuVasive by 5.4% in the first quarter. Geneva Advisors LLC now owns 16,814 shares of the medical device company’s stock worth $1,256,000 after buying an additional 860 shares during the last quarter. Cookson Peirce & Co. Inc. bought a new stake in shares of NuVasive during the first quarter worth approximately $237,000. Greenleaf Trust bought a new stake in shares of NuVasive during the first quarter worth approximately $443,000. Finally, Oregon Public Employees Retirement Fund raised its stake in shares of NuVasive by 1.1% in the first quarter. Oregon Public Employees Retirement Fund now owns 17,641 shares of the medical device company’s stock worth $1,317,000 after buying an additional 200 shares during the last quarter.
NUVA has been the subject of several research analyst reports. TheStreet raised NuVasive from a “c+” rating to a “b” rating in a research note on Wednesday, May 3rd. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $76.00 price objective on shares of NuVasive in a research note on Monday, May 15th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $84.00 price objective on shares of NuVasive in a research note on Friday, June 30th. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a research note on Wednesday, July 19th. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $80.00 price objective on shares of NuVasive in a research note on Friday, July 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company’s stock. NuVasive presently has a consensus rating of “Buy” and a consensus price target of $81.18.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.